Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06010329
NCT06010329RecruitingPhase 2

A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

Teligene US18 sites in 1 country66 target enrollmentStarted: December 27, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
66
Locations
18
Primary Endpoint
Objective Response Rate (ORR)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

Detailed Description

Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor. EGFR is a gene that makes a protein that is involved in cell growth and cell survival. Mutated (changed) forms of the EGFR gene and protein have been found in some types of cancer, including non-small cell lung cancer. These changes may cause cancer cells to grow and spread in the body. The purpose of this study is to explore how effective sutetinib maleate capsules are for the treatment of patients with locally advanced or metastatic NSCLC with uncommon EGFR mutations.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age 18 years old and above, male or female
  • •Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC
  • •Confirmation that the tumor harbors an uncommon epidermal growth factor receptor (EGFR) mutation (tumor tissue biopsy)
  • •At least one measurable lesion
  • •Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2
  • •A minimum life expectancy of > 3 months
  • •Adequate bone marrow reserve, hepatic, renal, and coagulation function
  • •Other inclusion criteria apply for participating in the study.

Exclusion Criteria

  • •Participant ever used the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) for anti-tumor therapy prior to enrollment (Cohort 1), or second generation EGFR TKI (Cohort 2)
  • •Any systemic anti-tumor therapy such as chemotherapy and radiation therapy (including curative radiotherapy or spinal radiotherapy portion >30%) used within 3 weeks prior to enrollment; immunotherapy within 4 weeks; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for the tumor within 2 weeks prior to enrollment; Cohort 2: any EGFR TKIs within 5 half-lives.
  • •Use or intake of drugs or foods containing potent inhibitors or inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 14 days or 5 half-lives, whichever is the longer, prior to enrollment
  • •Surgical operation (excluding aspiration biopsy) of main organs or a significant injury within 4 weeks prior to enrollment
  • •Any unresolved toxicities from prior therapy greater than National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAEv5.0) Grade 1, at the time of screening except for alopecia
  • •Inability to swallow the study medication, any seriously (NCI-CTCAEv5.0 ≥ Grade 3) chronic gastrointestinal disorder, malabsorption syndrome or any other conditions with influence on gastrointestinal absorption
  • •Active central nervous system metastases
  • •Any active infection which has not been controlled at screening
  • •Other exclusion criteria apply for participating in the Study.

Arms & Interventions

Single arm, Open label

Experimental

Participants will receive sutetinib maleate capsule taken orally with (preferred) or without food, at the dose directed by the Investigators, 28 days for a cycle.

Intervention: Sutetinib Maleate Capsule (Drug)

Outcomes

Primary Outcomes

Objective Response Rate (ORR)

Time Frame: Pre-dose up to approximately 32 months post-dose

Secondary Outcomes

  • Duration of Response (DoR)(Pre-dose up to approximately 32 months post-dose)
  • Disease Control Rate (DCR)(Pre-dose up to approximately 32 months post-dose)
  • Progression Free Survival (PFS)(Pre-dose up to approximately 32 months post-dose)
  • Time to Tumor Progression (TTP)(Pre-dose up to approximately 32 months post-dose)
  • Time to Response (TTR)(Pre-dose up to approximately 32 months post-dose)
  • Time to Treatment Failure (TTF)(Pre-dose up to approximately 32 months post-dose)
  • Overall Survival (OS)(Pre-dose up to approximately 32 months post-dose)
  • 1-year Progression Free Survival(Pre-dose up to 1 year post-dose)
  • 1-year Survival(Pre-dose up to 1 year post-dose)
  • Area Under The Curve (AUC) of Sutetinib Maleate Capsule(Pre-dose up to 24 hours post-dose)
  • Maximum Plasma Concentration (Cmax) of Sutetinib Maleate Capsule(Pre-dose up to 24 hours post-dose)
  • Minimum Plasma Concentration (Cmin) of Sutetinib Maleate Capsule(Pre-dose up to 24 hours post-dose)
  • Time to Peak Drug Concentration (Tmax) of Sutetinib Maleate Capsule(Pre-dose up to 24 hours post-dose)
  • Sutetinib Maleate Capsule half-life (T1/2)(Pre-dose up to 24 hours post-dose)
  • Apparent Clearance (CL/f) of Sutetinib Maleate Capsule(Pre-dose up to 24 hours post-dose)
  • Volume of Distribution (Vz/F) of Sutetinib Maleate Capsule(Pre-dose up to 24 hours post-dose)
  • Number of Participants Experiencing Adverse Events (AE)(Pre-dose up to approximately 32 months post-dose)
  • Number of Participants Experiencing Adverse Drug Reactions (ADR)(Pre-dose up to approximately 32 months post-dose)
  • Number of Participants Experiencing Serious Adverse Events (SAE)(Pre-dose up to approximately 32 months post-dose)
  • Number of Participants Experiencing Srious Adverse Reactions (SAR)(Pre-dose up to approximately 32 months post-dose)

Investigators

Sponsor
Teligene US
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (18)

Loading locations...

Similar Trials

Recruiting
Phase 2
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerNon-small Cell Lung Cancer
NCT05168566Teligene US99
Completed
Phase 2
Efficacy and Safety of Sunitinib in Metastatic Gastric CancerGastric AdenocarcinomaBarrett Esophagus
NCT00411151Johannes Gutenberg University Mainz52
Completed
Phase 2
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell CancerRenal Cell CancerKidney Cancer
NCT00465179M.D. Anderson Cancer Center61
Unknown
Phase 2
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS TherapyClassical Hodgkin LymphomaHodgkin Lymphoma (Category)Hodgkin DiseaseHodgkin Lymphoma
NCT03527628King Abdullah International Medical Research Center220
Completed
Phase 2
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)MZL
NCT03797456Beijing InnoCare Pharma Tech Co., Ltd.111